ClinicalTrials.gg
CompletedNCT05248945Updated Jan 15, 2026Results posted

DDI Study of Evobrutinib and Carbamazepine

A Phase 1 interventional study of Evobrutinib and Carbamazepine in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study was to investigate the effect of multiple doses of carbamazepine on two single doses of evobrutinib pharmacokinetics (PK) in healthy participants. Study details included:

Study Duration: up to 54 days. Treatment Duration: 25 days. Visit Frequency: Participants were residents in the Clinical Research Unit from Day 1 to Day 20 and returned on Day 26 for a Safety Follow-Up visit.

02

Conditions studied

  • Healthy

Keywords

  • Clinical Pharmacology
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of Participant and Disease Characteristics
  • Had a body weight within 50.0 and 100.0 kg (kilogram) (inclusive) and (BMI) within the range 19.0 and 30.0 kilogram per meter square (kg/m\^2) (inclusive)
  • Male: No and barrier requirements were needed. Female: Was not a woman of
  • Were capable of giving signed , which included compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol
  • Were stable nonsmokers for at least 3 months preceding Screening

Exclusion criteria

Exclusion Criteria:

  • Had a history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation
  • Had been administered or live-attenuated virus vaccines within 3 months prior to Screening. Administration of other types of vaccines (e.g., SARSCoV2 vaccines) was allowed until 2 weeks before admission to Clinical Research Unit (CRU), thereafter it was prohibited until the end of the study
  • Had been administered moderate or strong inhibitors or inducers of Cytochrome P450 (CYP)3A4/5 or Pgp within 4 weeks prior to the first administration of study intervention
  • Had a to carbamazepine (carbamazepine SmPC)
  • Had a history of any
  • Had a history of drug ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients; history of serious allergic reactions leading to hospitalization or any other hypersensitivity reaction in general, including contact hypersensitivity to (ECG) electrodes, which may have affected the safety of the participant and/or outcome of the study per the Investigator's discretion.
  • Other protocol defined exclusion criteria could have applied.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Evobrutinib plus Carbamazepine

    Participants received a single oral dose of Evobrutinib 45 mg on Day 1 and Day 19 under fed condition followed by Cabamazepine 100 mg on Days 2 and 3, 200 mg on Days 4 and 5 and then 300 mg from Days 6 to 19 and were titrated back to 200 mg from Days 20 to 22 and 100 mg on Days 23 to 25 twice daily.

    Drug: Evobrutinib · Drug: Carbamazepine

Interventions

  • Participants received a single oral dose of Evobrutinib 45 mg on Day 1 and Day 19

    Also known as: M2951

  • Participants received Carbamazepine 100 mg on Days 2 and 3, 200 mg on Days 4 and 5 and then 300 mg from Days 6 to 19 and were titrated back to 200 mg from Days 20 to 22 and 100 mg on Days 23 to 25 twice daily.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  2. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib

    Cmax was obtained from plasma concentration time curve.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 16 and 24 hours post dose on Day 1 and Day 19.

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs."

    Time frame: Baseline (Day 1) and Day 26

  2. Absolute Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values

    Blood samples were collected to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  3. Absolute Change From Baseline in Hematology Parameter: Hemoglobin Levels

    Blood samples were collected to analyze the hematology parameter: Hemoglobin levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  4. Absolute Change From Baseline in Hematology Parameter: Hematocrit Values

    Blood samples were collected to analyze the hematology parameter: Hematocrit Value. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  5. Absolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time

    Blood samples were collected to analyze the hematology parameter: Activated Partial Thromboplastin Time. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  6. Change From Baseline in Hematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/ Leukocytes, and Neutrophils/Leukocytes

    Blood samples were collected to analyze the hematology parameter: basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/ leukocytes, and neutrophils/leukocytes. The data in terms of 'percentage of cells' was calculated as: Count of Basophils (10\^9 cells/L) (or any other defined hematology parameter e.g. Neutrophils, Eosinophils etc.) divided by the total count of Leukocytes (10\^9 cells/L) in the blood multiplied by 100."

    Time frame: Baseline (Day 1) and Day 26

  7. Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  8. Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  9. Absolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

    Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value. Percent=Fraction×100

    Time frame: Baseline (Day 1) and Day 26

  10. Absolute Change From Baseline in Biochemistry Parameter: Bilirubin, Creatinine and Urate

    Blood samples were collected to analyze the Biochemistry Parameter: Bilirubin, Creatinine and Urate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  11. Absolute Change From Baseline in Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels

    Blood samples were collected to analyze the Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  12. Absolute Change From Baseline in Biochemistry Parameter: Protein and Albumin Levels

    Blood samples were collected to analyze the Biochemistry Parameter: Protein and Albumin Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  13. Absolute Change From Baseline in Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase

    Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  14. Absolute Change From Baseline in Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate Levels

    Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  15. Absolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate

    12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: Heart Rate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  16. Absolute Change From Baseline in 12-Lead ECG Parameter: RR Duration, QT Duration, Fridericia's Formula (QTcF), PR Duration and QRS Duration

    12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: RR Duration. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1) and Day 26

  17. Absolute Change From Baseline in Vital Sign: Blood Pressure

    Blood pressure (systolic and diastolic) was measured after at least 5 minutes resting, with the participant in the seated position without distractions.

    Time frame: Baseline (Day 1) and Day 26

  18. Absolute Change From Baseline in Vital Sign: Pulse Rate

    Pulse rate was measured after at least 5 minutes resting, with the subject in the seated position without distractions.

    Time frame: Baseline (Day 1) and Day 26

  19. Absolute Change From Baseline in Vital Sign: Respiratory Rate

    Respiratory Rate was measured after at least 5 minutes resting, with the participant in the seated position without distractions.

    Time frame: Baseline (Day 1) and Day 26

  20. Absolute Change From Baseline in Vital Sign: Body Temperature

    The absolute changes from baseline in Body Temperature (degree Celsius \[°C\]) were reported.

    Time frame: Baseline Day 1 and Day 26

  21. Total Body Clearance of Evobrutinib From Plasma (CL/f)

    CL/f was defined as the apparent total clearance of the drug from plasma after extravascular administration.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  22. Apparent Volume of Distribution (Vz/f) of Evobrutinib

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. The apparent volume of distribution during the terminal phase following extravascular administration and was calculated by using the formula=Dose/ (AUC0-inf\* λz).

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  23. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib

    The AUC from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  24. Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib

    Tmax was obtained directly from the concentration versus time curve.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  25. Apparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma

    t1/2 was defined as the time taken for the plasma concentration or the amount of drug in the body to be reduced by half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  26. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  27. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A)

    The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration was at or above LOQ. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  28. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)

    Cmax was obtained from plasma concentration time curve.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  29. Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A)

    Tmax was obtained directly from the concentration versus time curve.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  30. Time Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma

    The time prior to the first concentration at or above limit of quantification. It is calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  31. Metabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)

    Molecular weight-corrected ratio of metabolite (M) AUC0-inf to parent (P) AUC0-inf: M/P(AUC0-inf) = (AUC0-inf metabolite (MSC2729909A) \*molecular weight (MW) parent) / (AUC0-inf parent\*MW metabolite (MSC2729909A)).

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.

  32. Metabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)

    Molecular weight-corrected ratio of metabolite Cmax to parent Cmax: M/P(Cmax) = (Cmaxmetabolite (MSC2729909A) \* MWparent) / (Cmax parent \* MW metabolite (MSC2729909A)).

    Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.

  33. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity

    AE was defined as any untoward medical occurrence in a subject. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. SAE was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs. Severity of AE were assessed by the investigator as Mild, Moderate, and Severe: An event that prevents normal everyday activities. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe. SAS is used.

    Time frame: Baseline (Day 1) and Day 26

07

Results

Posted Jan 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneEvobrutinib + Carbamazepine
Started14
Completed12
Not completed2
Withdrew: Adverse event1
Withdrew: Elevated gamma-glutamyl transferase (ggt)1

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · Hour*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib
Hour*nanograms per milliliter (h*ng/mL)EvobrutinibEvobrutinib + Carbamazepine
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib310 ± 33.249.2 ± 23.1
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 15.83 · 90% CI 13.26 to 18.90
PrimaryMaximum Observed Plasma Concentration (Cmax) of Evobrutinib

Cmax was obtained from plasma concentration time curve.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
nanogram per milliliter (ng/mL)EvobrutinibEvobrutinib + Carbamazepine
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib132 ± 33.122.4 ± 33.1
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 17.03 · 90% CI 13.59 to 21.33
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs."

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Serious TEAEs
ParticipantsEvobrutinib + Carbamazepine
Any TEAE14
Any serious TEAE0
SecondaryAbsolute Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values

Blood samples were collected to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · 10^9 cells/Liter
Absolute Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values
10^9 cells/LiterEvobrutinib + Carbamazepine
Platelets11 ± 34.0
Leukocytes-0.23 ± 0.836
Neutrophils-0.18 ± 0.857
Eosinophils0.04 ± 0.064
Basophils0.03 ± 0.027
Monocytes-0.00 ± 0.111
Lymphocytes-0.12 ± 0.541
SecondaryAbsolute Change From Baseline in Hematology Parameter: Hemoglobin Levels

Blood samples were collected to analyze the hematology parameter: Hemoglobin levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · grams per liter (g/L)
Absolute Change From Baseline in Hematology Parameter: Hemoglobin Levels
grams per liter (g/L)Evobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Hemoglobin Levels-5.178 ± 8.4346
SecondaryAbsolute Change From Baseline in Hematology Parameter: Hematocrit Values

Blood samples were collected to analyze the hematology parameter: Hematocrit Value. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · litre of cells per litre of blood (L/L)
Absolute Change From Baseline in Hematology Parameter: Hematocrit Values
litre of cells per litre of blood (L/L)Evobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Hematocrit Values-0.014 ± 0.0236
SecondaryAbsolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time

Blood samples were collected to analyze the hematology parameter: Activated Partial Thromboplastin Time. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · seconds
Absolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time
secondsEvobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time-0.6 ± 1.29
SecondaryChange From Baseline in Hematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/ Leukocytes, and Neutrophils/Leukocytes

Blood samples were collected to analyze the hematology parameter: basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/ leukocytes, and neutrophils/leukocytes. The data in terms of 'percentage of cells' was calculated as: Count of Basophils (10\^9 cells/L) (or any other defined hematology parameter e.g. Neutrophils, Eosinophils etc.) divided by the total count of Leukocytes (10\^9 cells/L) in the blood multiplied by 100."

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Percentage of cells
Change From Baseline in Hematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/ Leukocytes, and Neutrophils/Leukocytes
Percentage of cellsEvobrutinib + Carbamazepine
Basophils/Leukocytes0.5 ± 0.44
Eosinophils/Leukocytes0.7 ± 0.98
Lymphocytes/Leukocytes0.1 ± 7.80
Monocytes/Leukocytes0.3 ± 2.11
Neutrophils/Leukocytes-1.6 ± 8.95
SecondaryAbsolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Picograms
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsEvobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin0.35557 ± 0.506080
SecondaryAbsolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Femtoliter
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterEvobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume1.4 ± 0.93
SecondaryAbsolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value. Percent=Fraction×100

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · percent
Absolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
percentEvobrutinib + Carbamazepine
Absolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio-0.04 ± 0.041
SecondaryAbsolute Change From Baseline in Biochemistry Parameter: Bilirubin, Creatinine and Urate

Blood samples were collected to analyze the Biochemistry Parameter: Bilirubin, Creatinine and Urate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · micromole/liter (umol/L)
Absolute Change From Baseline in Biochemistry Parameter: Bilirubin, Creatinine and Urate
micromole/liter (umol/L)Evobrutinib + Carbamazepine
Bilirubin-4.9 ± 2.91
Creatinine-1 ± 8.2
Urate-34.6 ± 59.35
SecondaryAbsolute Change From Baseline in Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels

Blood samples were collected to analyze the Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Millimoles per litre (mmol/L)
Absolute Change From Baseline in Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels
Millimoles per litre (mmol/L)Evobrutinib + Carbamazepine
Sodium Levels1 ± 1.6
Potassium Levels0.49 ± 0.407
Calcium Levels0.02 ± 0.084
Magnesium Levels0.05 ± 0.048
Phosphate Levels0.04 ± 0.210
SecondaryAbsolute Change From Baseline in Biochemistry Parameter: Protein and Albumin Levels

Blood samples were collected to analyze the Biochemistry Parameter: Protein and Albumin Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · g/L
Absolute Change From Baseline in Biochemistry Parameter: Protein and Albumin Levels
g/LEvobrutinib + Carbamazepine
Protein-4 ± 4.1
Albumin2.3 ± 2.61
SecondaryAbsolute Change From Baseline in Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase

Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Units per litre (U/L)
Absolute Change From Baseline in Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase
Units per litre (U/L)Evobrutinib + Carbamazepine
Alkaline Phosphatase8 ± 11
Amylase1 ± 9.1
Lipase2 ± 3.48
Creatine Kinase-33 ± 69.1
Gamma Glutamyl Transferase56 ± 49.4
Lactate Dehydrogenase-1 ± 22.1
Aspartate Aminotransferase9 ± 14.3
SecondaryAbsolute Change From Baseline in Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate Levels

Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · mmol/L
Absolute Change From Baseline in Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate Levels
mmol/LEvobrutinib + Carbamazepine
Glucose0.01 ± 0.439
Chloride2 ± 1.5
Cholesterol0.4 ± 0.60
Triglycerides0.2 ± 0.58
Phosphate0.04 ± 0.210
SecondaryAbsolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate

12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: Heart Rate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · beats per minute
Absolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate
beats per minuteEvobrutinib + Carbamazepine
Absolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate2 ± 6.6
SecondaryAbsolute Change From Baseline in 12-Lead ECG Parameter: RR Duration, QT Duration, Fridericia's Formula (QTcF), PR Duration and QRS Duration

12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: RR Duration. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Millisecond (msec)
Absolute Change From Baseline in 12-Lead ECG Parameter: RR Duration, QT Duration, Fridericia's Formula (QTcF), PR Duration and QRS Duration
Millisecond (msec)Evobrutinib + Carbamazepine
RR Duration-29 ± 94.9
QT Duration-1 ± 8.7
QTcF2 ± 8.8
PR Duration-2 ± 7.5
QRS Duration-1 ± 3.9
SecondaryAbsolute Change From Baseline in Vital Sign: Blood Pressure

Blood pressure (systolic and diastolic) was measured after at least 5 minutes resting, with the participant in the seated position without distractions.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · Millimeters of mercury (mmHg)
Absolute Change From Baseline in Vital Sign: Blood Pressure
Millimeters of mercury (mmHg)Evobrutinib + Carbamazepine
Systolic Blood Pressure-2 ± 8.6
Diastolic Blood Pressure-2 ± 4.8
SecondaryAbsolute Change From Baseline in Vital Sign: Pulse Rate

Pulse rate was measured after at least 5 minutes resting, with the subject in the seated position without distractions.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · beats per min
Absolute Change From Baseline in Vital Sign: Pulse Rate
beats per minEvobrutinib + Carbamazepine
Absolute Change From Baseline in Vital Sign: Pulse Rate2 ± 7.3
SecondaryAbsolute Change From Baseline in Vital Sign: Respiratory Rate

Respiratory Rate was measured after at least 5 minutes resting, with the participant in the seated position without distractions.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Mean · breaths per minute
Absolute Change From Baseline in Vital Sign: Respiratory Rate
breaths per minuteEvobrutinib + Carbamazepine
Absolute Change From Baseline in Vital Sign: Respiratory Rate-1 ± 3.3
SecondaryAbsolute Change From Baseline in Vital Sign: Body Temperature

The absolute changes from baseline in Body Temperature (degree Celsius \[°C\]) were reported.

Time frame:
Baseline Day 1 and Day 26
Reported as:
Mean · Degree Celsius
Absolute Change From Baseline in Vital Sign: Body Temperature
Degree CelsiusEvobrutinib + Carbamazepine
Absolute Change From Baseline in Vital Sign: Body Temperature0.1 ± 0.33
SecondaryTotal Body Clearance of Evobrutinib From Plasma (CL/f)

CL/f was defined as the apparent total clearance of the drug from plasma after extravascular administration.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · Litres per hour (L/h)
Total Body Clearance of Evobrutinib From Plasma (CL/f)
Litres per hour (L/h)EvobrutinibEvobrutinib + Carbamazepine
Total Body Clearance of Evobrutinib From Plasma (CL/f)145 ± 33.2914 ± 23.1
SecondaryApparent Volume of Distribution (Vz/f) of Evobrutinib

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. The apparent volume of distribution during the terminal phase following extravascular administration and was calculated by using the formula=Dose/ (AUC0-inf\* λz).

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/f) of Evobrutinib
LiterEvobrutinibEvobrutinib + Carbamazepine
Apparent Volume of Distribution (Vz/f) of Evobrutinib373 ± 20.01218 ± 28.4
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib

The AUC from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib
h*ng/mLEvobrutinibEvobrutinib + Carbamazepine
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib308 ± 33.446.1 ± 27.1
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 14.98 · 90% CI 12.60 to 17.82
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib

Tmax was obtained directly from the concentration versus time curve.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Median · hours
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib
hoursEvobrutinibEvobrutinib + Carbamazepine
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib2.00 (0.500 to 4.00)2.00 (1.50 to 3.00)
SecondaryApparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma

t1/2 was defined as the time taken for the plasma concentration or the amount of drug in the body to be reduced by half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Median · hours
Apparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma
hoursEvobrutinibEvobrutinib + Carbamazepine
Apparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma1.64 (0.997 to 2.89)0.961 (0.652 to 1.22)
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)
hour*ng/mLEvobrutinibEvobrutinib + Carbamazepine
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)115 ± 19.657.1 ± 20.1
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 49.66 · 90% CI 44.93 to 54.90
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A)

The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration was at or above LOQ. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A)
h*ng/mLEvobrutinibEvobrutinib + Carbamazepine
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A)113 ± 19.755.7 ± 21.3
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 49.41 · 90% CI 44.79 to 54.51
SecondaryMaximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)

Cmax was obtained from plasma concentration time curve.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · nanograms per milliliters (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)
nanograms per milliliters (ng/mL)EvobrutinibEvobrutinib + Carbamazepine
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)30.2 ± 23.421.0 ± 20.0
Statistical analysis
  • Evobrutinib vs Evobrutinib + Carbamazepine · Ratio of test and reference treatment: 69.65 · 90% CI 60.34 to 80.40
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A)

Tmax was obtained directly from the concentration versus time curve.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Median · hours
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A)
hoursEvobrutinibEvobrutinib + Carbamazepine
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A)2.50 (0.500 to 4.0)2.50 (1.50 to 4.00)
SecondaryTime Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma

The time prior to the first concentration at or above limit of quantification. It is calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Median · hours
Time Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma
hoursEvobrutinibEvobrutinib + Carbamazepine
Time Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma0.500 (0 to 1.52)0.500 (0 to 1.50)
SecondaryMetabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)

Molecular weight-corrected ratio of metabolite (M) AUC0-inf to parent (P) AUC0-inf: M/P(AUC0-inf) = (AUC0-inf metabolite (MSC2729909A) \*molecular weight (MW) parent) / (AUC0-inf parent\*MW metabolite (MSC2729909A)).

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)
RatioEvobrutinibEvobrutinib + Carbamazepine
Metabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)0.344 ± 31.01.11 ± 21.7
SecondaryMetabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)

Molecular weight-corrected ratio of metabolite Cmax to parent Cmax: M/P(Cmax) = (Cmaxmetabolite (MSC2729909A) \* MWparent) / (Cmax parent \* MW metabolite (MSC2729909A)).

Time frame:
Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)
RatioEvobrutinibEvobrutinib + Carbamazepine
Metabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)0.213 ± 23.60.870 ± 20.9
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity

AE was defined as any untoward medical occurrence in a subject. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. SAE was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs. Severity of AE were assessed by the investigator as Mild, Moderate, and Severe: An event that prevents normal everyday activities. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe. SAS is used.

Time frame:
Baseline (Day 1) and Day 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity
ParticipantsEvobrutinib + Carbamazepine
Mild14
Moderate7
Severe0

Adverse events

Collected over Baseline (Day 1) up to Day 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evobrutinib + Carbamazepine0/14 (0%)0/14 (0%)14/14 (100%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventEvobrutinib + Carbamazepine
DizzinessNervous system disorders7/14
SomnolenceNervous system disorders7/14
NauseaGastrointestinal disorders6/14
HeadacheNervous system disorders6/14
ConstipationGastrointestinal disorders3/14
VomitingGastrointestinal disorders3/14
FatigueGeneral disorders3/14
AstheniaGeneral disorders2/14
Coordination abnormalNervous system disorders2/14
DiplopiaEye disorders1/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Evobrutinib + Carbamazepine
Mean43 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Evobrutinib + Carbamazepine
Female2
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Evobrutinib + Carbamazepine
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Evobrutinib + Carbamazepine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, Bavaria, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jul 2022, 6 months.

Results were first posted in Jan 2026, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Feb 21, 2022
StartActual
Jan 13, 2022
Primary completionActual
Jul 18, 2022
CompletionActual
Jul 18, 2022
Results first posted
Jan 15, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05248945
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Jan 13, 2022
Primary completion
Jul 18, 2022
Completion
Jul 18, 2022
Results posted
Jan 15, 2026
Last update
Jan 15, 2026

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion